Background Choline, a gut microbiome metabolite, is associated with cardiovascular risk
and other chronic illnesses. The aim was to develop a high-throughput nuclear magnetic …

High circulating trimethylamine-N-oxide (TMAO) is associated with an increased risk of
cardiovascular disease and mortality in people with chronic kidney disease (CKD). In …

Intestinal microbiota and their metabolites affect systemic inflammation and kidney disease
outcomes. Here, we investigated the key metabolites associated with the acute kidney injury …

Epidemiologic and genomic studies have progressively improved our understanding of the
causation of hypertension and the complex relationship with diet and environment. The …

Increased plasma trimethylamine N‐oxide (TMAO) levels have been associated with
cardiovascular diseases (CVD). L‐carnitine induces TMAO elevation in human blood, and …

The profile of gut microbiota can vary according to host genetic and dietary characteristics,
and be influenced by disease state and environmental stressors. The uremic dysbiosis …

Trimethylamine N-oxide (TMAO), the N-oxide metabolite of trimethylamine (TMA), is a key
index in the determination of a wide variety of human cardiac or kidney diseases. A …

Recent clinical studies show a positive correlation between elevated plasma TMAO and
increased cardiovascular risk. However, the mechanism of the increase and biological …

Trimethylamine N-oxide (TMAO), a novel cardiovascular (CV) disease and mortality risk
marker, is a gut microbiota-derived metabolite as well. Recently, plasma concentrations of …

Previous studies suggested the potential associations of trimethylamine N-oxide (TMAO)
and its metabolic precursor L-carnitine with obesity. However, existing evidence is limited …